Search results
Roche Holding AG (OTCMKTS:RHHBY) Receives $40.00 Consensus Target Price from Brokerages
ETF DAILY NEWS· 2 days agoRoche Holding AG (OTCMKTS:RHHBY – Get Free Report) has earned an average rating of “Hold” from the seven brokerages that are presently covering the stock ...
Roche (RHHBY) Cancer Drug Gets Breakthrough Therapy Designation
Zacks via Yahoo Finance· 5 days agoRoche's (RHHBY) inavolisib gets Breakthrough Therapy Designation in the United States for advanced...
The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, Eli...
Zacks· 7 days ago...Free Report) , Viking Therapeutics (VKTX Quick QuoteVKTX - Free Report) , Altimmune (ALT Quick QuoteALT - Free Report) , Roche (RHHBY Quick QuoteRHHBY - Free Report) and Amgen (AMGN Quick QuoteAMGN - Free Report) .
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
Zacks· 3 days agoAstraZeneca (AZN) announces an ambitious target of achieving $80 billion in revenues by 2030. Pfizer (PFE) announces a multi-year, multi-phase cost reduction program.
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan...
Benzinga· 5 days agoThe Structure Therapeutics GPCR stock has been identified as a potential winner in the obesity drug...
Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why
Zacks via Yahoo Finance· 2 days agoSales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent...
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma...
Benzinga· 3 days agoThe Biden administration has urged the U.S. Supreme Court to reconsider a ruling involving 21...
Mairs & Power Growth Fund's 1st-Quarter Commentary: A Review
Guru Focus· 6 days agoThe market's performance continues to hinge on the “Magnificent 7” Technology stocks, which have...
Regeneron (REGN) Announces Positive Data on Oncology Candidate
Zacks· 3 days agoFree Report) announced positive new results from an ongoing phase I/II study on pipeline candidate REGN7075. The phase I/II first-in-human, open-label study is evaluating REGN7075, in combination ...
Emerging Trends in Oncology: ASCO 2024 Highlights Next-Gen Antibody-Drug Conjugates and More
WJET - WFXP Erie· 2 days agoUSA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual...